ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2233 • ACR Convergence 2022

    Machine Learning Uncovers Novel mRNAs Expressed in Fibromyalgia

    Lena Kolb1, Mark Rudolph1, Alan Kivitz2, Scott Rey1, Roberta Alexander1, Anja Kammesheidt3 and Geoffrey Stephens1, 1Exagen, Inc., Vista, CA, 2Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, 3self, Laguna Beach, CA

    Background/Purpose: Fibromyalgia is a debilitating pain condition that affects roughly 12 million people in the United States. Although preliminary diagnostic criteria have been established by…
  • Abstract Number: 2238 • ACR Convergence 2022

    Performance of the 2016 ACR/EULAR Myositis Response Criteria in Adult Dermatomyositis and Polymyositis Therapeutic Trials and Consensus Profiles

    Didem Saygin1, Hanna Kim2, Christian Douglas3, Brian Erman3, Jesse Wilkerson3, john mcgrath3, Chester Oddis4, Ingrid Lundberg5, Anthony Amato6, Ignacio Garcia-De La Torre7, Hector Chinoy8, David Fiorentino9, Lorinda Chung9, Yeong-Wook Song10, Katalin Danko11, Frederick Miller12, Nicola Ruperto13, Jiří Vencovský14, Rohit Aggarwal15 and Lisa G Rider12, 1University of Chicago, Chicago, IL, 2Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences; Juvenile Myositis Therapeutic and Translation Studies Unit, PTRB, NIAMS, NIH, Bethesda, MD, 3Social and Scientific Systems, Inc., Durham, NC, 4University of Pittsburgh, Pittsburgh, PA, 5Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, 6Harvard University, Boston, MA, 7Centro de Est. de Inv. Bas. y Clinica, S.C., Guadalajara, Mexico, 8The University of Manchester, Sale, United Kingdom, 9Stanford University, Stanford, CA, 10Seoul National University, Seoul, Republic of Korea, 11*Deceased, Debrecen, Hungary, 12Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD, 13IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy, 14Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 15Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: The ACR/EULAR myositis response criteria (MRC) were developed as a composite continuous measure (Total Improvement Score (TIS)) using absolute percent changes (abs%) in 6…
  • Abstract Number: 2241 • ACR Convergence 2022

    Autoantibodies and Damage in Patients with Idiopathic Inflammatory Myopathies: A Longitudinal Multicenter Study from the EuroMyositis International Network

    Fabricio Espinosa-Ortega1, Karin Lodin2, Marie Holmqvist1, Maryam Dastmalchi3, Angela Ceribelli4, Jiri Venkovsky5, Hector Chinoy6, Louise Diederichsen7, Samuel Shinjo8, Ingrid Lundberg9 and Helene Alexanderson1, 1Karolinska Institutet, Stockholm, Sweden, 2Karolinska University hospital, Huddinge, Sweden, 3Karolinska University Hospital, Stockholm, Sweden, 4Humanitas Research Hospital, Humanitas University, Rozzano (MI) Italy, Borgo San Giacomo, Italy, 5Charles Univ Prague, Inst Rheumatol, Prague, Czech Republic, Prague, Czech Republic, 6The University of Manchester, Sale, United Kingdom, 7Copenhagen University Hospital, Rigshospitalet, Dragør, Denmark, 8Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, Brazil, 9Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Patients with idiopathic inflammatory myopathies (IIM) may harbor autoantibodies that are associated with well-defined clinical phenotypes. The association of these autoantibodies with level of…
  • Abstract Number: 2240 • ACR Convergence 2022

    Autoimmunity Against Melanoma Differentiation-Associated Protein 5 Advances Acute Lung Injury to Interstitial Lung Disease in Mice

    Yuki Ichimura1, Risa Konishi1, Toshifumi Nomura2, Manabu Fujimoto3 and Naoko Okiyama1, 1Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan, 2University of Tsukuba, Tsukuba, Ibaraki, Japan, 3Osaka University, Suita, Japan

    Background/Purpose: Anti-melanoma differentiation-associated protein 5 (MDA5) antibody-positive dermatomyositis (DM) is characterized by amyopathic DM with interstitial lung disease (ILD). Patients with anti-MDA5 antibody-associated DM sometimes…
  • Abstract Number: 2237 • ACR Convergence 2022

    Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Subcutaneous Abatacept in Adults with Active Idiopathic Inflammatory Myopathy: Results of the 24-Week Double-Blind and 28-Week Open-Label Periods

    Rohit Aggarwal1, Ingrid Lundberg2, Yeong-Wook Song3, Aziz Shaibani4, Victoria Werth5 and Michael Maldonado6, 1Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 2Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, 3Seoul National University, Seoul, Republic of Korea, 4Nerve and Muscle Center of Texas, Houston, TX, 5Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, 6Bristol Myers Squibb, Princeton, NJ

    Background/Purpose: A 52-week (wk), randomized, placebo (PBO)-controlled phase 3 trial of subcutaneous (SC) abatacept (ABA) and standard of care (SOC) was performed in patients (pts)…
  • Abstract Number: 2219 • ACR Convergence 2022

    Time-Dependent Evaluation of Glucocorticoid Exposure Duration and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis

    Beth Wallace1, Yuqing Gao2, H. Myra Kim3, Punyasha Roul4, Ted Mikuls5, Daniel Clauw6, Bryant England7, Joshua Baker8, Brian Sauer9, Grant Cannon10, Shirley Cohen-Mekelberg1, Wyndy Wiitala2, Jeremy Sussman1, Rodney Hayward1 and Akbar Waljee1, 1University of Michigan Department of Internal Medicine; Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, 2Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, 3Center for Statistical Consultation and Research, University of Michigan; Center for Clinical Management Research, VA Ann Arbor Healthcare Center, Ann Arbor, MI, 4UNMC, Omaha, NE, 5Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 6University of Michigan Department of Anesthesia, Ann Arbor, MI, 7University of Nebraska Medical Center, Omaha, NE, 8University of Pennsylvania, Philadelphia, PA, 9Salt Lake City VA/University of Utah, Salt Lake City, UT, 10Retired, Salt Lake City, UT

    Background/Purpose: Three-quarters of RA patients use glucocorticoids (GC) at some point to manage RA symptoms. Prior work suggests recent GC use is associated with major…
  • Abstract Number: 2198 • ACR Convergence 2022

    How Did a Mandatory Switching Policy for Biosimilars in Canada Impact Uptake and Spending?

    Alison McClean1, Nick Bansback1, Lucy Cheng1, Fiona Clemont2, Mina Tadrous3, Mark Harrison1 and Mike Law1, 1University of British Columbia, Vancouver, BC, Canada, 2University of Calgary, Calgary, AB, Canada, 3University of Toronto, Toronto, ON, Canada

    Background/Purpose: Uptake of biosimilars has been suboptimal in North America. In 2019, British Columbia (BC) became the first jurisdiction in North America to require patients…
  • Abstract Number: 2244 • ACR Convergence 2022

    Salient Coping Strategies Among Youth with Chronic Musculoskeletal Pain

    Sabrina Gmuca1, Daneka Stryker2, Mackenzie McGill1, Whitney Eriksen3 and Peter F. Cronholm4, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2Drexel University College of Medicine, Philadelphia, PA, 3Jefferson Health, Philadelphia, PA, 4University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Youth with chronic musculoskeletal pain (CMP) learn pain-coping strategies and build resilience through cognitive behavioral therapy (CBT). In order to expand therapeutic options for…
  • Abstract Number: 2248 • ACR Convergence 2022

    Prevalence and Mortality of Interstitial Lung Abnormalities in Rheumatoid Arthritis and non-RA Comparators in a Multicenter Prospective Cohort

    Gregory McDermott1, Keigo Hayashi2, Kazuki Yoshida1, Matthew Moll1, Michael Cho1, Tracy Doyle1, Paul Dellaripa1, Rachel Putman1, Raul San Jose Estepar1, George Washko1, Elizabeth Regan3, Hiroto Hatabu1, Gary M Hunninghake1, Edwin Silverman1 and Jeffrey Sparks4, 1Brigham and Women's Hospital, Boston, MA, 2Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 3National Jewish Health, Denver, CO, 4Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Subpleural interstitial lung abnormalities (ILA) may be a form of subclinical or preclinical interstitial lung disease (ILD) and have been reported in up to…
  • Abstract Number: 2245 • ACR Convergence 2022

    Feasibility and Efficacy of a Peer Education Program to Improve Patient Engagement in Lupus Clinical Trials

    Saira Sheikh1, Caroline Donovan2, Carla Menezes2, Albert T. Roy2, Andrew Simkus3, Diane Gross4, Anca Askanase5, Rosalind Ramsey-Goldman6, Vikas Majithia7, Nicole Wanty3, Annie McNeill3, Kristen Holtz3 and S. Sam Lim8, 1University of North Carolina at Chapel Hill, Chapel Hill, NC, 2Lupus Therapeutics, LLC, New York, NY, 3KDH Research & Communication, Atlanta, GA, 4Lupus Research Alliance, New York, NY, 5Columbia University Medical Center, New York, NY, 6Northwestern University Feinberg School of Medicine, Chicago, USA, Chicago, IL, 7University of Mississippi Medical Center, Ridgeland, MS, 8Emory University, Atlanta, GA

    Background/Purpose: To assess outcomes related to Lupus Therapeutics' Patient Advocates for Lupus Studies (LT-PALS) a peer-to-peer clinical trial (CT) education program designed to improve CT…
  • Abstract Number: 2249 • ACR Convergence 2022

    Impact of Interstitial Lung Disease on COVID-19 Severity Among Patients with Rheumatoid Arthritis: A Multicenter Comparative Study

    Gabriel Figueroa Parra1, Emily Gilbert2, Maria Valenzuela Almada1, Sebastian Vallejo1, Matthew Neville3, Naomi Patel4, Claire Cook5, Xiaoqing Fu5, Ramla Hagi5, Gregory McDermott6, Michael Dilorio6, Lucy Masto6, Kathleen Vanni6, Emily Kowalski6, Grace Qian6, Zachary Wallace5, Ali Duarte-Garcia1 and Jeffrey Sparks7, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Jacksonville, FL, 3Mayo Clinic, Phoenix, AZ, 4Massachusetts General Hospital, Sale Creek, TN, 5Massachusetts General Hospital, Boston, MA, 6Brigham and Women's Hospital, Boston, MA, 7Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Rheumatoid arthritis (RA) has been associated with severe COVID-19, but few studies have investigated outcomes in RA phenotypes such as interstitial lung disease (RA-ILD),…
  • Abstract Number: 2251 • ACR Convergence 2022

    Reduction in Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk in Patients Treated with Tofacitinib

    Matthew Baker1, Yuhan Liu1, Rong Lu1, Janice Lin1, Jason Melehani1 and William Robinson2, 1Stanford University, Stanford, CA, 2Stanford University School of Medicine, Palo Alto, CA

    Background/Purpose: Clinically significant interstitial lung disease (ILD) occurs in roughly 10% of patients with rheumatoid arthritis (RA). There are limited data on the pathogenesis of…
  • Abstract Number: 2250 • ACR Convergence 2022

    Genetic and Environmental Risk Factors in Rheumatoid Arthritis-Associated Interstitial Lung Disease

    Austin Wheeler1, Yangyuna Yang1, Joshua Baker2, Jill Poole1, Dana Ascherman3, Gail Kerr4, Andreas Reimold5, Gary Kunkel6, Grant Cannon7, Katherine Wysham8, Namrata Singh9, Deana Lazaro10, Paul Monach11, S. Louis Bridges, Jr.12, Ted Mikuls13 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3University of Pittsburgh, Pittsburgh, PA, 4Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 5University of Texas Southwestern Medical Center, Dallas, TX, 6University of Utah, Salt Lake City, UT, 7Retired, Salt Lake City, UT, 8VA Puget Sound/University of Washington, Seattle, WA, 9University of Washington, Bellevue, WA, 10VA New York Harbor Healthcare system, Short Hills, NJ, 11VA Boston Healthcare System, Boston, MA, 12Hospital for Special Surgery, New York, NY, 13Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: RA-associated interstitial lung disease (RA-ILD) is an extra-articular manifestation of RA causing substantial morbidity and mortality. Genetic risk variants, such as the MUC5B rs35705950…
  • Abstract Number: 2255 • ACR Convergence 2022

    Do Fatty Lesions Explain the Association Between Inflammation and New Syndesmophytes in Patients with Radiographic Axial Spondyloarthritis?

    Rosalinde Stal1, Alexandre Sepriano2, Sofia Ramiro1, floris van Gaalen1, Pedro Machado3, Xenofon Baraliakos4, Manouk de Hooge5, Rosaline van den Berg1, Monique Reijnierse1, Juergen Braun6, Robert Landewé7 and Désirée van der Heijde8, 1Leiden University Medical Center, Leiden, Netherlands, 2Leiden University Medical Centre, Portela Loures, Portugal, 3University College London, London, United Kingdom, 4Rheumazentrum Ruhrgebiet Herne, Herne, Germany, 5Ghent University Hospital, Luxembourg, Luxembourg, 6Rheumazentrum Ruhrgebiet, Herne, Germany, 7Amsterdam University Medical Center, Meerssen, Netherlands, 8Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands

    Background/Purpose: Presence of vertebral corner inflammation (VCI) increases the likelihood of a new syndesmophyte in the same vertebral corner (VC) in patients with r-axSpA. It…
  • Abstract Number: 2254 • ACR Convergence 2022

    Detection of Active Inflammatory and Structural Changes Indicative of Axial Spondyloarthritis on MRI of Sacroiliac Joint Using a Deep Learning Framework

    Keno Kyrill Bressem1, Lisa Adams1, Fabian Proft2, Kay-Geert Hermann3, Torsten Diekhoff1, Laura Spiller1, Stefan Niehues1, Marcus Makowski4, Bernd Hamm1, Mikhail Protopopov5, valeria Rios-Rodriguez6, Hildrun Haibel7, Judith Rademacher5, Murat Torgutalp7, Robert G Lambert8, Xenofon Baraliakos9, Walter P Maksymowych10, Janis Vahldiek1 and Denis Poddubnyy2, 1Charité – Universitätsmedizin Berlin, Berlin, Germany, 2Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 3Charité - Universitätsmedizin Berlin, Berlin, Germany, 4Technical University of Munich, Munich, Germany, 5Charité Universitätsmedizin Berlin, Berlin, Germany, 6Charité-Universitätsmedizin Berlin, Berlin, Germany, 7Charité - Universitätsmedizin, Berlin, Berlin, Germany, 8University of Alberta, Edmonton, AB, Canada, 9Rheumazentrum Ruhrgebiet Herne, Herne, Germany, 10Department of Medicine, University of Alberta, Edmonton, AB, Canada

    Background/Purpose: Magnetic resonance tomography (MRI) plays a key role in the early diagnosis of axial spondyloarthritis (axSpA). However, the detection of changes indicative of axSpA…
  • « Previous Page
  • 1
  • …
  • 670
  • 671
  • 672
  • 673
  • 674
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology